Inventor · disambiguated record
Anker J. Hansen
Also filed as: HANSEN ANKER J · HANSEN ANKER JON
7 granted patents·5 pending applications·61 citations·filing 1982–2023
85Inventor score
Top patents by PatentIndex Score
12 records- 0192US10882916B2Anti-C5a receptor antibodiesNOVO NORDISK AS·Filed 2019·Granted Jan 5, 2021·6 cites·14 claims
- 0289US10323097B2Anti-C5a receptor antibodiesNOVO NORDISK AS·Filed 2016·Granted Jun 18, 2019·8 cites·19 claims
- 0385US2024218076A1Therapeutic antibodiesNOVO NORDISK AS·Filed 2023·Application pending·0 cites
- 0475US8455504B2Inhibition of the activity of the capsaicin receptor in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance or insulin resistanceGRAM DORTE XENIA·Filed 2010·Granted Jun 4, 2013·6 cites·8 claims
- 0572US2021238300A1Therapeutic antibodiesNOVO NORDISK AS·Filed 2020·Application pending·0 cites
- 0667US7879866B2Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disordersDORTE XENIA GRAM·Filed 2005·Granted Feb 1, 2011·2 cites·5 claims
- 0763US2015044231A1Therapeutic AntibodiesNOVO NORDISK AS·Filed 2014·Application pending·0 cites
- 0859US4480929AMethod and a device for measuring concrete maturityHANSEN ANKER J·Filed 1982·Granted Nov 6, 1984·20 cites·3 claims
- 0957US5683989ATreatment of ischemias by administration of 2,N6 -substituted adenosinesNOVO NORDISK AS·Filed 1995·Granted Nov 4, 1997·13 cites·32 claims
- 1045US2002045610A1Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesisFiled 2001·Application pending·0 cites
- 1143US5484774A2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemiasNOVO NORDISK AS·Filed 1993·Granted Jan 16, 1996·6 cites·28 claims
- 1242US2006188476A1Interleukin 20 (IL-20) and its use in neovascularisationNOVO NORDISK AS·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →